Umeå based HiloProbe has entered a partnership with the major international company Biocartis Group.
This is a strategically important step for HiloProbe in their aim to reach out globally with its colorectal cancer test-product, ColoNode, they state.
“We are very happy to start a collaboration and a long-term relationship with Biocartis, which strengthens our focus on colorectal cancer thanks to Biocartis’ established sales and distribution network across many countries,” says Lina Olsson, CEO of HiloProbe.
Initial focus
The partnership between HiloProbe and Biocartis, a molecular diagnostics company based in Mechelen, Belgium, will initially focus on the commercialization of the ColoNode CE-marked IVD manual kit in selected European countries by Biocartis.
Following commercial uptake of the manual kit, HiloProbe and Biocartis will consider developing a fully automated version of the test on Biocartis’ decentralized Idylla platform.
“We are pleased to partner with HiloProbe on the distribution of the ColoNode kit. This allows us to broaden our product offering to customers in the colorectal cancer domain, complementing tests for RAS biomarkers and MSI on our Idylla platform. The collaboration supports our mission to maximize patient access to precision medicine in oncology,” says Roger Moody, CEO of Biocartis.
Photo of Lina Olsson: HiloProbe
